Article Per Year (5 Year)
p-Index From 2020 - 2025
0.961
P-Index
This Author published in this journals
All Journal Bioscientia Medicina : Journal of Biomedicine and Translational Research Bioscientia Medicina : Journal of Biomedicine and Translational Research
Irvan Medison
Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Andalas/Dr. M. Djamil General Hospital, Padang, Indonesia
Biochemistry, Genetics & Molecular Biology Immunology & microbiology Medicine & Pharmacology Neuroscience

Published : 6 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 6 Documents
Search

 1 
Management of Pulmonary Tuberculosis in Liver Cirrhosis: A Case Report Hadya Gorga; Irvan Medison; Dewi Wahyu F.
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 7 No. 3 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v7i3.784

Abstract

Background: Anti-tuberculosis drugs (OAT) are metabolized in the liver and have a high potential for hepatotoxicity, and will increase the risk of drug-induced liver injury (DILI). This study aimed to describe the management of pulmonary tuberculosis in patients with cirrhosis of the liver. Case presentation: 45 years old male patient with cough with phlegm for 5 months, weight loss. The patient is also known to have cirrhosis of the liver. From the results of the bacteriological examination, it was found that TCM mtb was detected as high. The patient has risk factors for low BMI, a history of alcohol, hypo albumin, and comorbid hepatic cirrhosis. This patient was given a hepatoprotection. After liver function improved, the patient was started on anti-tuberculosis drugs with a regimen of 2 hepatotoxic drugs, namely isoniazid, rifampin, and ethambutol, given gradually and planned to be given for 9 months, with regular monitoring of liver function in the first 2 months. Conclusion: Effective management of pulmonary tuberculosis infection depends on giving OAT at the appropriate dose and duration. The selection of regimen and duration of therapy can be considered based on the condition of chronic liver disease. Careful assessment and periodic evaluation of liver function are required.
Management of Pulmonary Tuberculosis in Liver Cirrhosis: A Case Report Hadya Gorga; Irvan Medison; Dewi Wahyu F.
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 7 No. 3 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v7i3.784

Abstract

Background: Anti-tuberculosis drugs (OAT) are metabolized in the liver and have a high potential for hepatotoxicity, and will increase the risk of drug-induced liver injury (DILI). This study aimed to describe the management of pulmonary tuberculosis in patients with cirrhosis of the liver. Case presentation: 45 years old male patient with cough with phlegm for 5 months, weight loss. The patient is also known to have cirrhosis of the liver. From the results of the bacteriological examination, it was found that TCM mtb was detected as high. The patient has risk factors for low BMI, a history of alcohol, hypo albumin, and comorbid hepatic cirrhosis. This patient was given a hepatoprotection. After liver function improved, the patient was started on anti-tuberculosis drugs with a regimen of 2 hepatotoxic drugs, namely isoniazid, rifampin, and ethambutol, given gradually and planned to be given for 9 months, with regular monitoring of liver function in the first 2 months. Conclusion: Effective management of pulmonary tuberculosis infection depends on giving OAT at the appropriate dose and duration. The selection of regimen and duration of therapy can be considered based on the condition of chronic liver disease. Careful assessment and periodic evaluation of liver function are required.
Overview of Interleukin-6 Levels in COVID-19 (Coronavirus Disease 2019) Patients at Dr. M. Djamil General Hospital, Padang, Indonesia Adhika Rahman; Irvan Medison; Afriani Afriani
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 7 No. 3 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v7i3.787

Abstract

Background: COVID-19 infection can cause an exaggerated immune response. This immune response is associated with an increase in proinflammatory cytokines, especially interleukin-6 (IL-6). High IL-6 levels are found in the acute stage of COVID-19, and IL-6 can induce an excessive humoral inflammatory response. This study aimed to provide an overview of IL-6 levels in coronavirus disease 2019 (COVID-19) patients at Dr. M. Djamil General Hospital, Padang, Indonesia. Methods: Descriptive observational study of 102 research subjects. Observations on sociodemographic, clinical, and laboratory data were carried out in this study. Univariate analysis was carried out using SPSS version 25. Results: Patients with symptom onset <7 days had higher IL-6 levels than those with an onset of more than 7 days. Patients with critical degrees have the highest IL-6 levels compared to moderate and severe degrees. Patients with more than 1 comorbid had higher IL-6 levels than patients who had no comorbid or only had 1 comorbid. Patients with <21 days of treatment had higher IL-6 levels than patients with more than 21 days of treatment. Conclusion: COVID-19 patients at Dr. M. Djamil General Hospital, Padang, Indonesia, with an onset of less than 7 days, a critical degree, and more than 1 comorbidity have higher IL-6 levels.
Overview of Interleukin-6 Levels in COVID-19 (Coronavirus Disease 2019) Patients at Dr. M. Djamil General Hospital, Padang, Indonesia Adhika Rahman; Irvan Medison; Afriani Afriani
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 7 No. 3 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v7i3.787

Abstract

Background: COVID-19 infection can cause an exaggerated immune response. This immune response is associated with an increase in proinflammatory cytokines, especially interleukin-6 (IL-6). High IL-6 levels are found in the acute stage of COVID-19, and IL-6 can induce an excessive humoral inflammatory response. This study aimed to provide an overview of IL-6 levels in coronavirus disease 2019 (COVID-19) patients at Dr. M. Djamil General Hospital, Padang, Indonesia. Methods: Descriptive observational study of 102 research subjects. Observations on sociodemographic, clinical, and laboratory data were carried out in this study. Univariate analysis was carried out using SPSS version 25. Results: Patients with symptom onset <7 days had higher IL-6 levels than those with an onset of more than 7 days. Patients with critical degrees have the highest IL-6 levels compared to moderate and severe degrees. Patients with more than 1 comorbid had higher IL-6 levels than patients who had no comorbid or only had 1 comorbid. Patients with <21 days of treatment had higher IL-6 levels than patients with more than 21 days of treatment. Conclusion: COVID-19 patients at Dr. M. Djamil General Hospital, Padang, Indonesia, with an onset of less than 7 days, a critical degree, and more than 1 comorbidity have higher IL-6 levels.
Delayed SARS-COV-2 Viral Clearance in a Newly Diagnosed HIV Patient: A Case Series Dimas Bayu Firdaus; Oea Khairsyaf; Dewi Wahyu; Irvan Medison; Deddy Herman; Masrul Basyar
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 7 No. 6 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v7i6.836

Abstract

Background: SARS-CoV-2 can infect anyone, but people with HIV have underlying conditions or comorbidities that can make them seriously ill if infected with SARS-CoV-2. HIV attacks and destroys the immune system delays the response of specific antibodies, and even causes failure to thrive, resulting in a long course of the disease. This case report aimed to describe 2 cases of HIV patients co-infected with SARS-CoV-2 with delayed viral clearance. Case presentation: There are two HIV patients with co-infection with SARS-CoV-2. The first patient, a 32-year-old man with COVID-19 and HIV-AIDS, was referred from a regional hospital after being treated for 10 days due to clinical deterioration. Physical examination showed that the patient's general condition was moderately ill, and other vital signs were within normal limits. Oral candidiasis was seen in the patient's mouth, crackles were found in both lung fields, and epigastric tenderness was found on abdominal examination. The patient tested positive for COVID-19 based on the results of an antigen swab examination from the previous hospital. The second patient, a 26-year-old man, came with complaints of intermittent fever 1 week before entering the hospital. Complaints began with the body feeling weak and coughing without phlegm 2 weeks ago. The patient tested positive for COVID-19 based on the results of an antigen swab examination. The delayed viral clearance of SARS-CoV-2 in the two patients was possibly caused by the impaired immune response due to HIV infection, as shown by the presence of lymphopenia and decreased CD4+. Conclusion: ARV use can suppress HIV viral load and increase immunity so that can help viral clearance of SARS-CoV-2.
Delayed SARS-COV-2 Viral Clearance in a Newly Diagnosed HIV Patient: A Case Series Dimas Bayu Firdaus; Oea Khairsyaf; Dewi Wahyu; Irvan Medison; Deddy Herman; Masrul Basyar
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 7 No. 6 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v7i6.836

Abstract

Background: SARS-CoV-2 can infect anyone, but people with HIV have underlying conditions or comorbidities that can make them seriously ill if infected with SARS-CoV-2. HIV attacks and destroys the immune system delays the response of specific antibodies, and even causes failure to thrive, resulting in a long course of the disease. This case report aimed to describe 2 cases of HIV patients co-infected with SARS-CoV-2 with delayed viral clearance. Case presentation: There are two HIV patients with co-infection with SARS-CoV-2. The first patient, a 32-year-old man with COVID-19 and HIV-AIDS, was referred from a regional hospital after being treated for 10 days due to clinical deterioration. Physical examination showed that the patient's general condition was moderately ill, and other vital signs were within normal limits. Oral candidiasis was seen in the patient's mouth, crackles were found in both lung fields, and epigastric tenderness was found on abdominal examination. The patient tested positive for COVID-19 based on the results of an antigen swab examination from the previous hospital. The second patient, a 26-year-old man, came with complaints of intermittent fever 1 week before entering the hospital. Complaints began with the body feeling weak and coughing without phlegm 2 weeks ago. The patient tested positive for COVID-19 based on the results of an antigen swab examination. The delayed viral clearance of SARS-CoV-2 in the two patients was possibly caused by the impaired immune response due to HIV infection, as shown by the presence of lymphopenia and decreased CD4+. Conclusion: ARV use can suppress HIV viral load and increase immunity so that can help viral clearance of SARS-CoV-2.
Co-Authors Adhika Rahman Afriani Afriani Dewi Wahyu Dewi Wahyu F. Dimas Bayu Firdaus Hadya Gorga Herman, Deddy Masrul Basyar Oea Khairsyaf